Agilent (A) AI Stock Analysis

• Market Cap: $35.26B
• Dividend Yield: 0.8%
• Average Volume (3M): 1.67M
• Price to Earnings (P/E): 29.5
• Beta (1Y): 1.01
• Revenue Growth: 4.48%
• EPS Growth: -11.52%
• Country: US
• Employees: 17,900
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.37
• Shares Outstanding: 283,500,430
• 10 Day Avg. Volume: 1,673,815
• 30 Day Avg. Volume: 1,673,961
• PEG Ratio: 4.64
• Price to Book (P/B): 5.29
• Price to Sales (P/S): 4.79
• P/FCF Ratio: 22.73
• Enterprise Value/Market Cap: 0.98
• Enterprise Value/Revenue: 5.10
• Enterprise Value/Gross Profit: 9.62
• Enterprise Value/Ebitda: 19.25
• 1Y Price Target: $140.82
• Price Target Upside: 15.53% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 12

• Rating: 77 Outperform
• Price Target: $139.00 ▲(14.04% Upside)

Agilent's strong financial performance and positive earnings call are the most significant factors contributing to its score. The company's solid profitability and raised guidance highlight its robust position in the industry. However, high valuation and mixed technical indicators slightly temper the overall outlook.

Positive Factors

Revenue Growth

Agilent's consistent revenue growth, marked by a fifth consecutive quarter of acceleration, underscores its strong market position and effective strategies.

Innovation and Product Development

The EU certification of Agilent's diagnostic panel enhances its product portfolio, supporting long-term growth in the diagnostics market.

Cost Management

Agilent's focus on cost management through its Ignite model boosts operational efficiency, supporting margin sustainability and profitability.

Negative Factors

Tariff and Margin Pressures

Ongoing tariff costs and margin pressures could hinder Agilent's profitability, posing challenges to maintaining its competitive edge.

Rising Debt Levels

Rising debt levels may strain Agilent's financial flexibility, potentially impacting its ability to invest in growth opportunities.

US Market Challenges

Challenges in key US markets could limit Agilent's growth potential, affecting its ability to capitalize on domestic opportunities.

Agilent Business Overview & Revenue Model

Company Description

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

How the Company Makes Money

Agilent generates revenue through multiple streams, primarily from the sale of its analytical instruments, consumables, and services. The company’s revenue model is heavily reliant on its product sales, which includes both hardware and software, alongside ongoing services and support contracts. Key revenue streams include the sale of high-margin consumables that accompany their instrumentation, maintenance agreements, and software licenses. Additionally, Agilent benefits from strategic partnerships with organizations in various industries, enhancing its market reach and product offerings. The company also invests in research and development to innovate and expand its product lines, which contributes to sustained revenue growth.

Agilent Financial Statement Overview

Summary

Agilent's financial performance is strong, with solid profitability and efficient operations. The income statement shows consistent margins, though revenue growth has been inconsistent. The balance sheet is robust, but rising debt levels need monitoring. Cash flow is positive, indicating good cash management despite some volatility.

Income Statement

Agilent's income statement reflects strong profitability with a consistent gross profit margin above 50% and a solid net profit margin around 18-19%. The EBIT and EBITDA margins are healthy, indicating efficient operations. However, the revenue growth rate has been inconsistent, with a slight decline in recent periods, which could be a concern for future growth.

Balance Sheet

The balance sheet is robust with a moderate debt-to-equity ratio around 0.5, suggesting manageable leverage. Return on equity is strong, consistently above 19%, indicating effective use of equity. The equity ratio is stable, reflecting a solid capital structure. However, the increase in total debt over recent periods should be monitored.

Cash Flow

Agilent's cash flow statement shows a positive trend in free cash flow growth, particularly in the TTM period. The operating cash flow to net income ratio is strong, indicating good cash generation relative to earnings. The free cash flow to net income ratio is also healthy, suggesting efficient cash management. However, fluctuations in free cash flow growth in previous years highlight potential volatility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.79B	6.51B	6.83B	6.85B	6.32B	5.34B
Gross Profit	3.60B	3.54B	3.46B	3.72B	3.41B	2.84B
EBITDA	1.80B	1.87B	1.70B	1.91B	1.76B	1.23B
Net Income	1.22B	1.29B	1.24B	1.25B	1.21B	719.00M
Balance Sheet
Total Assets	12.23B	11.85B	10.76B	10.53B	10.71B	9.63B
Cash, Cash Equivalents and Short-Term Investments	1.53B	1.33B	1.59B	1.05B	1.57B	1.44B
Total Debt	3.41B	3.57B	2.73B	2.77B	2.73B	2.36B
Total Liabilities	5.86B	5.95B	4.92B	5.23B	5.32B	4.75B
Stockholders Equity	6.37B	5.90B	5.84B	5.30B	5.39B	4.87B
Cash Flow
Free Cash Flow	1.40B	1.37B	1.47B	1.02B	1.30B	802.00M
Operating Cash Flow	1.50B	1.75B	1.77B	1.31B	1.49B	921.00M
Investing Cash Flow	-1.26B	-1.26B	-310.00M	-338.00M	-749.00M	-147.00M
Financing Cash Flow	-490.00M	-752.00M	-930.00M	-1.37B	-696.00M	-717.00M

Agilent Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 121.89
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For A, the sentiment is Negative. The current price of 121.89 is below the 20-day moving average (MA) of 125.94, above the 50-day MA of 120.73, and below the 200-day MA of 122.91, indicating a neutral trend. The MACD of 1.07 indicates Positive momentum. The RSI at 44.92 is Neutral, neither overbought nor oversold. The STOCH value of 23.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for A.

Agilent Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
A	77 Outperform	$35.26B	29.53	19.88%	0.80%	4.48%	-11.52%
IQV	77 Outperform	30.81B	25.59	21.41%	―	3.53%	-10.72%
TMO	72 Outperform	176.72B	27.09	13.03%	0.37%	2.05%	7.03%
DHR	69 Neutral	133.12B	39.49	6.52%	0.68%	-3.24%	-16.60%
WAT	69 Neutral	17.42B	25.94	30.62%	―	5.89%	10.61%
MTD	60 Neutral	25.59B	30.64	-320.62%	―	3.11%	8.50%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Agilent Corporate Events

Agilent CFO Resignation Announced, Interim Replacement Named

On July 11, 2025, Agilent Technologies announced the resignation of Robert W. McMahon, its Senior Vice President and Chief Financial Officer, effective July 31, 2025, due to personal reasons. Rodney Gonsalves, the current Vice President, Corporate Controller, and Principal Accounting Officer, will serve as interim CFO. Agilent remains confident in its long-term plans and expects its third-quarter financial results to align with previous guidance.